Total Intravenous Anesthesia with Propofol Reduces Postoperative Nausea and Vomiting in Patients Undergoing Robot-Assisted Laparoscopic Radical Prostatectomy: A Prospective Randomized Trial

Young-Chul Yoo,1,2* Sun-Joon Bai,1,2* Ki-Young Lee,1,2 Seokyung Shin,1,2 Eun Kyeong Choi,1 and Jong Wha Lee1,3

Department of 1Anesthesiology and Pain Medicine, 2Anesthesia and Pain Research Institute, 3Division of Anesthesiology and Pain Medicine, Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea.

Received: April 16, 2012
Revised: May 8, 2012
Accepted: May 8, 2012
Corresponding author: Dr. Jong Wha Lee, Division of Anesthesiology and Pain Medicine, Cardiovascular Hospital, Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Korea.
Tel: 82-2-2228-8516, Fax: 82-2-364-2951
E-mail: jhanes@yuhs.ac

*Young-Chul Yoo and Sun-Joon Bai contributed equally to this work.

The authors have no financial conflicts of interest.

INTRODUCTION

Robot-assisted laparoscopic radical prostatectomy (RLRP) has gained popularity since it was first introduced in 2001, and is widely replacing conventional open prostatectomy. RLRP entails benefits of reduced blood loss, nerve sparing, less...
Sixty two male patients scheduled for RLRP, with an American Society of Anesthesiologists physical status of I or II, ranging in age from 50 to 70 years, were enrolled. To control the anticipated risk for PONV, we excluded patients with a history of motion sickness or PONV, antiemetic use within 24 hours before surgery, regular corticosteroid use, chemotherapy within 4 weeks or radiotherapy within 8 weeks, hepatic dysfunction, confirmed renal impairment, or obesity (body mass index >35 kg/m²). Patients were randomly allocated to either the balanced anesthesia (Des group) or TIVA (TIVA group) group by means of random numbers generated by a computer. Antiemetic prophylaxis was commonly administered in both groups. A physician of the anesthesiology preoperative evaluation clinic who was not involved in the current trial performed randomization and assignment.

All patients were premedicated intravenously with midazolam 0.05 mg/kg and glycopyrrolate 0.2 mg at 1 hour and just before the induction of anesthesia, respectively. Standard monitoring devices were applied. In the TIVA group, propofol and remifentanil were concurrently infused using a target controlled infusion (TCI) system for induction and maintenance of anesthesia. Effect site concentration was controlled using the Marsh, et al. 

We designed a prospective single-site, double-blinded, randomized, and parallel-arm controlled trial to investigate the effects of TIVA with propofol on PONV in patients undergoing RLRP in comparison to balanced anesthesia with desflurane. The primary endpoint was to compare the incidence and severity of PONV for 48 hours postoperatively.

MATERIALS AND METHODS

This trial was conducted at Yonsei University College of Medicine, Seoul, Korea, between November 2010 and May 2011. In addition to gaining the approval of the Institutional Review Board of Yonsei University College of Medicine (4-2010-0361) and registration with clinicaltrial.gov (Unique Identifier: NCT01402622), this study was performed in full compliance with the Declaration of Helsinki. All participants were recruited from the anesthesiology preoperative evaluation clinic and provided written informed consent. Sixty two male patients scheduled for RLRP, with an American Society of Anesthesiologists physical status of I or II, ranging in age from 50 to 70 years, were enrolled. To control the anticipated risk for PONV, we excluded patients with a history of motion sickness or PONV, antiemetic use within 24 hours before surgery, regular corticosteroid use, chemotherapy within 4 weeks or radiotherapy within 8 weeks, hepatic dysfunction, confirmed renal impairment, or obesity (body mass index >35 kg/m²). Patients were randomly allocated to either the balanced anesthesia (Des group) or TIVA (TIVA group) group by means of random numbers generated by a computer. Antiemetic prophylaxis was commonly administered in both groups. A physician of the anesthesiology preoperative evaluation clinic who was not involved in the current trial performed randomization and assignment.

All patients were premedicated intravenously with midazolam 0.05 mg/kg and glycopyrrolate 0.2 mg at 1 hour and just before the induction of anesthesia, respectively. Standard monitoring devices were applied. In the TIVA group, propofol and remifentanil were concurrently infused using a target controlled infusion (TCI) system for induction and maintenance of anesthesia. Effect site concentration was controlled using the Marsh, et al. 

We designed a prospective single-site, double-blinded, randomized, and parallel-arm controlled trial to investigate the effects of TIVA with propofol on PONV in patients undergoing RLRP in comparison to balanced anesthesia with desflurane. The primary endpoint was to compare the incidence and severity of PONV for 48 hours postoperatively.

MATERIALS AND METHODS

This trial was conducted at Yonsei University College of Medicine, Seoul, Korea, between November 2010 and May 2011. In addition to gaining the approval of the Institutional Review Board of Yonsei University College of Medicine (4-2010-0361) and registration with clinicaltrial.gov (Unique Identifier: NCT01402622), this study was performed in full compliance with the Declaration of Helsinki. All participants were recruited from the anesthesiology preoperative evaluation clinic and provided written informed consent. Sixty two male patients scheduled for RLRP, with an American Society of Anesthesiologists physical status of I or II, ranging in age from 50 to 70 years, were enrolled. To control the anticipated risk for PONV, we excluded patients with a history of motion sickness or PONV, antiemetic use within 24 hours before surgery, regular corticosteroid use, chemotherapy within 4 weeks or radiotherapy within 8 weeks, hepatic dysfunction, confirmed renal impairment, or obesity (body mass index >35 kg/m²). Patients were randomly allocated to either the balanced anesthesia (Des group) or TIVA (TIVA group) group by means of random numbers generated by a computer. Antiemetic prophylaxis was commonly administered in both groups. A physician of the anesthesiology preoperative evaluation clinic who was not involved in the current trial performed randomization and assignment.

All patients were premedicated intravenously with midazolam 0.05 mg/kg and glycopyrrolate 0.2 mg at 1 hour and just before the induction of anesthesia, respectively. Standard monitoring devices were applied. In the TIVA group, propofol and remifentanil were concurrently infused using a target controlled infusion (TCI) system for induction and maintenance of anesthesia. Effect site concentration was controlled using the Marsh, et al. 

We designed a prospective single-site, double-blinded, randomized, and parallel-arm controlled trial to investigate the effects of TIVA with propofol on PONV in patients undergoing RLRP in comparison to balanced anesthesia with desflurane. The primary endpoint was to compare the incidence and severity of PONV for 48 hours postoperatively.

MATERIALS AND METHODS

This trial was conducted at Yonsei University College of Medicine, Seoul, Korea, between November 2010 and May 2011. In addition to gaining the approval of the Institutional Review Board of Yonsei University College of Medicine (4-2010-0361) and registration with clinicaltrial.gov (Unique Identifier: NCT01402622), this study was performed in full compliance with the Declaration of Helsinki. All participants were recruited from the anesthesiology preoperative evaluation clinic and provided written informed consent. Sixty two male patients scheduled for RLRP, with an American Society of Anesthesiologists physical status of I or II, ranging in age from 50 to 70 years, were enrolled. To control the anticipated risk for PONV, we excluded patients with a history of motion sickness or PONV, antiemetic use within 24 hours before surgery, regular corticosteroid use, chemotherapy within 4 weeks or radiotherapy within 8 weeks, hepatic dysfunction, confirmed renal impairment, or obesity (body mass index >35 kg/m²). Patients were randomly allocated to either the balanced anesthesia (Des group) or TIVA (TIVA group) group by means of random numbers generated by a computer. Antiemetic prophylaxis was commonly administered in both groups. A physician of the anesthesiology preoperative evaluation clinic who was not involved in the current trial performed randomization and assignment.

All patients were premedicated intravenously with midazolam 0.05 mg/kg and glycopyrrolate 0.2 mg at 1 hour and just before the induction of anesthesia, respectively. Standard monitoring devices were applied. In the TIVA group, propofol and remifentanil were concurrently infused using a target controlled infusion (TCI) system for induction and maintenance of anesthesia. Effect site concentration was controlled using the Marsh, et al. 

We designed a prospective single-site, double-blinded, randomized, and parallel-arm controlled trial to investigate the effects of TIVA with propofol on PONV in patients undergoing RLRP in comparison to balanced anesthesia with desflurane. The primary endpoint was to compare the incidence and severity of PONV for 48 hours postoperatively.

MATERIALS AND METHODS

This trial was conducted at Yonsei University College of Medicine, Seoul, Korea, between November 2010 and May 2011. In addition to gaining the approval of the Institutional Review Board of Yonsei University College of Medicine (4-2010-0361) and registration with clinicaltrial.gov (Unique Identifier: NCT01402622), this study was performed in full compliance with the Declaration of Helsinki. All participants were recruited from the anesthesiology preoperative evaluation clinic and provided written informed consent. Sixty two male patients scheduled for RLRP, with an American Society of Anesthesiologists physical status of I or II, ranging in age from 50 to 70 years, were enrolled. To control the anticipated risk for PONV, we excluded patients with a history of motion sickness or PONV, antiemetic use within 24 hours before surgery, regular corticosteroid use, chemotherapy within 4 weeks or radiotherapy within 8 weeks, hepatic dysfunction, confirmed renal impairment, or obesity (body mass index >35 kg/m²). Patients were randomly allocated to either the balanced anesthesia (Des group) or TIVA (TIVA group) group by means of random numbers generated by a computer. Antiemetic prophylaxis was commonly administered in both groups. A physician of the anesthesiology preoperative evaluation clinic who was not involved in the current trial performed randomization and assignment.

All patients were premedicated intravenously with midazolam 0.05 mg/kg and glycopyrrolate 0.2 mg at 1 hour and just before the induction of anesthesia, respectively. Standard monitoring devices were applied. In the TIVA group, propofol and remifentanil were concurrently infused using a target controlled infusion (TCI) system for induction and maintenance of anesthesia. Effect site concentration was controlled using the Marsh, et al. 

We designed a prospective single-site, double-blinded, randomized, and parallel-arm controlled trial to investigate the effects of TIVA with propofol on PONV in patients undergoing RLRP in comparison to balanced anesthesia with desflurane. The primary endpoint was to compare the incidence and severity of PONV for 48 hours postoperatively.
RESULTS

RLRP was performed as planned in all patients and complete data sets from the 62 patients were analyzed without any missing data.

Patients’ characteristics were similar between the two groups (Table 1). Preoperative and intraoperative variables associated with PONV, including Apfel score, anesthesia time, operating time, and fluid balances, were similar between the two groups (Table 2).

Because no significant differences were found between the groups after 6 hours postoperatively, data on postoperative nausea and vomiting were presented for three time periods (PACU, 1-6 hours, and 6-48 hours) to discriminate immediate, early and late postoperative incidences (Table 3). The overall incidence of nausea during the first 48 hours postoperatively was significantly lower in the TIVA group compared to the Des group ($p=0.004$). The incidences of nausea during PACU stay and at postoperative 1-6 hours...
were significantly lower in the TIVA group, compared to the Des group \((p=0.023\) and 0.001, respectively), but not significantly different at 6-48 hours postoperatively.

VNRS at PACU and 1-6 hours postoperatively was significantly lower in the TIVA group compared to the Des group \((p=0.043\) and 0.001, respectively). VNRS at 6-48 hours postoperatively were not significantly different between the two groups. In the Des group, retching developed in 4 and 6 patients, vomiting was reported in 1 and 3 patients, and rescue antiemetic drug was administered in 4 and 8 patients at the PACU and postoperative 1-6 hours, respectively. However, none of the patients in the TIVA group demonstrated retching, vomiting, or rescue antiemetic requirement during the same periods (Table 3).

The incidence of moderate to severe PONV during the first 48 hours postoperatively was significantly lower in the TIVA group \([2 (6.5\%)]\) compared to the Des group \([10 (32.3\%), p=0.01]\), especially in the PACU \([0 (0\%)\) vs. 6 (19.4\%), \(p=0.01]\) and at postoperative 1-6 hours \([0 (0\%)\) vs. 8 (25.8\%), 0.002\] (Fig. 1).

Pain intensity and the number of patients who required rescue analgesics were comparable between the two groups (Table 4).

**DISCUSSION**

In this prospective, double-blinded, randomized, and parallel-arm controlled trial, TIVA with propofol reduced not only the

---

**Table 3. Postoperative Nausea and Vomiting Associated Variables**

| Variables                           | Des (n=31) | TIVA (n=31) |
|-------------------------------------|------------|-------------|
| Patients with presence of nausea    |            |             |
| PACU                                | 7 (22.6)   | 1 (3.2)*    |
| 1-6 hrs                             | 17 (54.8)  | 5 (16.1)*   |
| 6-48 hrs                            | 6 (19.4)   | 5 (16.1)    |
| Total                               | 18 (58.1)  | 7 (22.6)*   |
| VNRS                                |            |             |
| PACU                                | 0.9±1.7    | 0.2±0.7*    |
| 1-6 hrs                             | 2.1±2.4    | 0.4±0.8*    |
| 6-48 hrs                            | 1±2.3      | 0.5±1.1     |
| Total                               | 7 (22.6)   | 2 (6.5)     |
| Patients with retching              |            |             |
| PACU                                | 4 (12.9)   | 0 (0)*      |
| 1-6 hrs                             | 6 (19.4)   | 0 (0)*      |
| 6-48 hrs                            | 3 (9.7)    | 2 (6.5)     |
| Total                               | 7 (22.6)   | 2 (6.5)     |
| Patients with vomiting              |            |             |
| PACU                                | 1 (3.2)    | 0 (0)       |
| 1-6 hrs                             | 3 (9.7)    | 0 (0)       |
| 6-48 hrs                            | 1 (3.2)    | 1 (3.2)     |
| Total                               | 4 (12.9)   | 1 (3.2)     |
| Patients with rescue antiemetics    |            |             |
| PACU                                | 4 (12.9)   | 0 (0)*      |
| 1-6 hrs                             | 8 (25.8)   | 0 (0)*      |
| 6-48 hrs                            | 2 (6.5)    | 2 (6.5)     |
| Total                               | 7 (22.6)   | 2 (6.5)     |

PACU, post anesthetic care unit; total, during 48 hours after the operation; VNRS, verbal numerical rating scale; Des, patients receiving balanced anesthesia; TIVA, patients receiving total intravenous anesthesia; SD, standard deviation.

**Table 4. Postoperative Pain Associated Variables**

| Variables                           | Des (n=31) | TIVA (n=31) |
|-------------------------------------|------------|-------------|
| VAS                                 |            |             |
| PACU                                | 42.9±17.1  | 41.9±18.3   |
| 1-6 hrs                             | 42.5±18.3  | 40.3±15.4   |
| 6-24 hrs                            | 33.5±14.5  | 34.5±11.5   |
| 24-48 hrs                           | 22.2±10.8  | 21.3±9.2    |
| Patients with rescue analgesics     |            |             |
| PACU                                | 12 (38.7)  | 12 (38.7)   |
| 1-6 hrs                             | 8 (25.8)   | 8 (25.8)    |
| 6-24 hrs                            | 5 (16.1)   | 3 (9.7)     |
| 24-48 hrs                           | 2 (6.5)    | 2 (6.5)     |
| Total                               | 21 (67.7)  | 17 (54.8)   |

VAS, visual analogue scale; PACU, post anesthetic care unit; total, during 48 hours after the operation; Des, patients receiving balanced anesthesia; TIVA, patients receiving total intravenous anesthesia; SD, standard deviation.

Values are presented as mean±SD or number of patients (%). *\(p<0.05\) vs. Des group.

---

**Fig. 1.** The incidence of moderate to severe PONV during postoperative 48 hours. PONV, postoperative nausea and vomiting; patients with moderate to severe PONV, patients with VNRS ≥4 or with retching or vomiting at either time period; Des, patients receiving balanced anesthesia; TIVA, patients receiving total intravenous anesthesia; PACU, post anesthetic care unit; VNRS, verbal numerical rating scale. *\(p<0.05\) vs. Des group.
incidence, but also the severity of PONV when compared to balanced anesthesia with desflurane in patients at low risk of PONV immediately after RLRP.

The cause of PONV is not yet fully understood. Multiple factors, including patient-related factors, type of the surgical procedure, or choice of the anesthetics, are considered possible etiologies of PONV.12,13 Despite the fact that the patients in the Des group exhibited only one or no patient-related risk factors for PONV and all received ramosetron as prophylaxis, the incidence of PONV was 58.1%, which is much higher than the incidence of 36% after laparoscopic cholecystectomy.18 Although anesthetized with desflurane and remifentanil, the higher incidence of PONV in the Des group in our study might be attributable to the surgery (RLRP). In laparoscopic surgery, prolonged pneumoperitoneum is known to increase the risk of PONV by 60% of the baseline value for every 30 minutes of extended operating time.5,6,12 In this study, the mean operating time of RLRP was 147 min. This is much longer than the mean operating time of laparoscopic cholecystectomy, which was recently reported to be only 35 min.19 As RLRP usually requires prolonged intraperitoneal CO₂ insufflations, resulting in high intraabdominal pressure, this may have contributed to the higher incidence of PONV in the Des group.

Propofol is known to exert an antiemetic effect even though the exact mechanism is still unclear. One study reported that propofol reduces PONV by blocking the 5-hydroxy-tryptamin-3 receptor of the serotonergic system,20,21 while others reported that inhibition of the chemoreceptor trigger zone and vagal nuclei, which are directly related to nausea and vomiting, is associated with the antiemetic effect of propofol.22

Several studies showed that patients administered propofol anesthesia had less PONV than those with other anesthetics.22-25 However, one suggested that propofol anesthesia demonstrated superiority in preventing PONV only for the immediate postoperative period at the PACU.24 Tramèr, et al.25 also put the antiemetic effect of propofol in doubt, as propofol exhibited a clinically relevant effect on PONV only for short-term period. Some studies suggested that the pro-emetogenic effect of inhalation anesthetics must be considered as an important cause of early PONV within 2 hours, and the antiemetic effect of propofol may originate from a lack of such an early emetogenic effect.27,28 In our study, we found that TIVA with propofol reduced the incidence and severity of PONV at postoperative 0-6 hours, compared to balanced anesthesia with desflurane. Although the TIVA group showed lower incidences of nausea, retching, and vomiting, and less VNRS at postoperative 6-48 hours compared to the Des group, no significant difference was observed between the two anesthetic methods after postoperative 6 hours. Our results are in agreement with a recent study,29 in which TIVA with propofol was shown to exert a preventive effect on PONV at early postoperative periods (0-6 hours) compared to isoflurane. As the antiemetic effect of propofol was shown to be maintained further beyond 2 hours postoperatively in both investigations, these results could provide evidence for the early antiemetic effect of propofol. In contrast to Grundmann, et al.,30 who reported no difference in the incidences of PONV between TIVA with propofol and desflurane/N₂O in patients undergoing short surgical procedures after propofol bolus induction, the incidence of PONV was significantly lower in the TIVA group compared to the Des group in our study. Therefore, much longer use of propofol with TIVA might be effective in preventing PONV for a longer period than the use of propofol for induction only.

Previous studies have recommended TIVA with propofol as the anesthetic method for patients at high risk for PONV.12,13,15 Although patients in this study involved fewer patient-related risk factors for PONV, the surgical method itself (RLRP) led to a higher incidence of PONV at the early postoperative period in the Des group, compared to the patients administered TIVA with propofol. Moreover, TIVA with propofol was shown to reduce the severity of PONV at 6 hours postoperatively. Therefore, anesthesia with TIVA along with propofol could be beneficial for preventing and mitigating PONV at early postoperative periods in patients undergoing RLRP.

The limitation of this study is that VNRS was used to assess the severity of nausea, which solely depends on the memory of the patients. Therefore, there might be bias in regards to patient’s ability to recall the severity of their nausea symptoms.

In conclusion, in order to prevent PONV after RLRP in early postoperative periods, anesthesia using TIVA with propofol could suffice, regardless of patient-related risk factors.

ACKNOWLEDGEMENTS

This study was supported by a faculty research grant of Yonsei University College of Medicine for 2007 (6-2007-0190).
REFERENCES

1. Zorn KC, Gofrit ON, Orvieto MA, Mikhail AA, Zagaja GP, Shalhav AL. Robotic-assisted laparoscopic prostatectomy: functional and pathologic outcomes with interfascial nerve preservation. Eur Urol 2007;51:755-62.

2. Jung JH, Arkoncel FR, Lee JW, Oh CK, Yusoff NA, Kim KJ, et al. Initial clinical experience of simultaneous robot-assisted bilateral partial nephrectomy and radical prostatectomy. Yonsei Med J 2012;53:236-9.

3. Meiningen D, Byhahn C, Bueck M, Binder J, Kramer W, Kessler P, et al. Effects of prolonged pneumoperitoneum on hemodynamics and acid-base balance during totally endoscopic robot-assisted radical prostatectomies. World J Surg 2002;26:1423-7.

4. Iitomi T, Torturni S, Kondo A, Akazawa T, Nakahara T. [Incidence of nausea and vomiting after cholecystectomy performed via laparotomy or laparoscopy]. Masui 1995;44:1627-31.

5. Watcha MF, White PF. Postoperative nausea and vomiting. Its etiology, treatment, and prevention. Anesthesiology 1992;77:162-84.

6. Kovac AL. Prevention and treatment of postoperative nausea and vomiting. Drugs 2000;59:213-43.

7. Chen X, Tang J, White PF, Wender RH, Quon R, Sloninsky A, et al. The effect of timing of dolasetron administration on its efficacy as a prophylactic antiemetic in the ambulatory setting. Anesth Analg 2001;93:906-11.

8. Gold BS, Kitz DS, Lecky JH, Neuhaus JM. Unanticipated admission to the hospital following ambulatory surgery. JAMA 1989;262:3008-10.

9. Apfel CC, Läärä E, Koivuranta M, Greim CA, Roewer N. A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. Anesthesiology 1999;91:693-700.

10. Leebenchom-Mansour MH, Pandit SK, Kotthary SP, Randel GL, Levy L. Desflurane versus propofol anesthesia: a comparative analysis in outpatients. Anesth Analg 1993;76:936-41.

11. Gupta A, Steier T, Zackernan R, Sakina N, Parker SD, Fleisher LA. Comparison of recovery profile after ambulatory anesthesia with propofol, isoflurane, sevoflurane and desflurane: a systematic review. Anesth Analg 2004;98:632-41.

12. Fujii Y. Management of postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy. Surg Endosc 2011;25:691-5.

13. Habib AS, Gan TJ. Evidence-based management of postoperative nausea and vomiting: a review. Can J Anaesth 2004;51:326-41.

14. White PF, O’Hara JF, Roberson CR, Wender RH, Candioti KA; POST-OP Study Group. The impact of current antiemetic practices on patient outcomes: a prospective study on high-risk patients. Anesth Analg 2008;107:452-8.

15. Apfel CC, Korttika I, Abdalla M, Kerger H, Turan A, Vedder I, et al. A factorial trial of six interventions for the prevention of post-operative nausea and vomiting. N Engl J Med 2004;350:2441-51.

16. Marsh B, White M, Morton N, Kenny GN. Pharmacokinetic model driven infusion of propofol in children. Br J Anaesth 1991;67:41-8.

17. Minto CF, Schneider TW, Egan TD, Youngs E, Lemmens HJ, Gambus PL, et al. Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. Anesthesiology 1997;86:10-23.

18. Fanelli G, Bertì M, Casati A. Fast-track anaesthesia for laparoscopic cholecystectomy: a prospective, randomized, multicentre, blind comparison of desflurane-remifentanil or sevoflurane-remifentanil. Eur J Anaesthesiol 2006;23:361-8.

19. Khan JS, Hasan H, Iqbal M. Laparoscopic cholecystectomy; common bile duct injury after learning curve. Professional Med J 2010;17:373-8.

20. Baram M, Göthert M, Fink K, Bönisch H. Inhibition by anaesthetics of 14C-guanidinium flux through the voltage-gated sodium channel and the cation channel of the S-HT3 receptor of N1E-115 neuroblastoma cells. Naunyn Schmiedebergs Arch Pharmacol 1993;347:125-32.

21. Vasileiou I, Xanthis T, Koudouna E, Perreira D, Klonaris C, Katrygrys A, et al. Propofol: a review of its non-anaesthetic effects. Eur J Pharmacol 2009;605:1-8.

22. Appadu BL, Strange PG, Lambert DG. Does propofol interact with D2 dopamine receptors? Anesth Analg 1994;79:1191-2.

23. Sneyd JR, Carr A, Byrom WD, Bilska AJ. A meta-analysis of nausea and vomiting following maintenance of anaesthesia with propofol or inhalational agents. Eur J Anaesthesiol 1998;15:433-45.

24. Fredman B, Nathanson MH, Smith I, Wang J, Klein K, White PF. Sevoflurane for outpatient anaesthesia: a comparison with propofol. Anesth Analg 1995;81:823-8.

25. Graham SG, Attenhead AR. A comparison between propofol and desflurane anaesthesia for minor gynaecological laparoscopic surgery. Anaesthesia 1993;48:471-5.

26. Tramer M, Moore A, McQuay H. Propofol anaesthesia and postoperative nausea and vomiting: quantitative systematic review of randomized controlled studies. Br J Anaesth 1997;78:247-55.

27. Apfel CC, Kranke P, Katz MH, Goeftert C, Papenfuss T, Rauch S, et al. Volatile anaesthetics may be the main cause of early but not delayed postoperative vomiting: a randomized controlled trial of factorial design. Br J Anaesth 2002;88:659-68.

28. Naylor RJ, Inall FC. The physiology and pharmacology of postoperative nausea and vomiting. Anaesthesia 1994;49 Suppl:2-5.

29. Gecai-Gashi A, Hashimi M, Sada F, Bafitu N, Salah N, Terzifa H, et al. Propofol vs isoflurane anesthesia-incidence of PONV in patients at maxillofacial surgery. Adv Med Sci 2010;55:308-12.

30. Grundmann U, Utth M, Eichner A, Wilhelm W, Larsen R. Total intravenous anaesthesia with propofol and remifentanil in paediatric patients: a comparison with a desflurane-nitrous oxide inhalation anaesthesia. Acta Anaesthesiol Scand 1998;42:945-50.